Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiopulmonary Exercise Testing Provides Prognostic Information in Advanced Cystic Fibrosis Lung Disease.
Radtke T, Urquhart DS, Braun J, Barry PJ, Waller I, Petch N, Mei-Zahav M, Kramer MR, Hua-Huy T, Dinh-Xuan AT, Innes JA, McArthur S, Sovtic A, Gojsina B, Verges S, de Maat T, Morrison L, Wood J, Crute S, Williams CA, Tomlinson OW, Bar-Yoseph R, Hebestreit A, Quon BS, Kwong E, Saynor ZL, Causer AJ, Stephenson AL, Schneiderman JE, Shaw M, Dwyer T, Stevens D, Remus N, Douvry B, Foster K, Benden C, Ratjen F, Hebestreit H; Prognostic Value of CPET in CF Study Group. Radtke T, et al. Among authors: ratjen f. Ann Am Thorac Soc. 2024 Mar;21(3):411-420. doi: 10.1513/AnnalsATS.202304-317OC. Ann Am Thorac Soc. 2024. PMID: 37879036 Free PMC article.
Disease Manifestations in Siblings with Primary Ciliary Dyskinesia.
Gatt D, Shaw M, McCoy J, Kritzinger F, Solomon M, Dell S, Ratjen F. Gatt D, et al. Among authors: ratjen f. Ann Am Thorac Soc. 2024 Jan;21(1):173-175. doi: 10.1513/AnnalsATS.202308-747RL. Ann Am Thorac Soc. 2024. PMID: 37903339 No abstract available.
Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
Sadras I, Kerem E, Livnat G, Sarouk I, Breuer O, Reiter J, Gileles-Hillel A, Inbar O, Cohen M, Gamliel A, Stanleigh N, Gunawardena T, Bartlett C, Gonska T, Moraes T, Eckford PDW, Bear CE, Ratjen F, Kerem B, Wilschanski M, Shteinberg M, Cohen-Cymberknoh M. Sadras I, et al. Among authors: ratjen f. J Cyst Fibros. 2023 Nov;22(6):1062-1069. doi: 10.1016/j.jcf.2023.06.001. Epub 2023 Jun 16. J Cyst Fibros. 2023. PMID: 37331863
Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
Streibel C, Willers CC, Pusterla O, Bauman G, Stranzinger E, Brabandt B, Bieri O, Curdy M, Bullo M, Frauchiger BS, Korten I, Krüger L, Casaulta C, Ratjen F, Latzin P, Kieninger E. Streibel C, et al. Among authors: ratjen f. J Cyst Fibros. 2023 Jul;22(4):615-622. doi: 10.1016/j.jcf.2022.12.012. Epub 2023 Jan 10. J Cyst Fibros. 2023. PMID: 36635199
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.
Schwarzenberg SJ, Vu PT, Skalland M, Hoffman LR, Pope C, Gelfond D, Narkewicz MR, Nichols DP, Heltshe SL, Donaldson SH, Frederick CA, Kelly A, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Solomon GM, Stalvey MS, Clancy JP, Rowe SM, Freedman SD; Promise Study Group. Schwarzenberg SJ, et al. Among authors: ratjen f. J Cyst Fibros. 2023 Mar;22(2):282-289. doi: 10.1016/j.jcf.2022.10.003. Epub 2022 Oct 21. J Cyst Fibros. 2023. PMID: 36280527 Free PMC article.
485 results